Surmodics (SRDX) News Today → Free report reveals “two-baggers” for 2024 (From TradingTips) (Ad) Free SRDX Stock Alerts $34.62 +0.54 (+1.58%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Stock Price Crosses Above 200 Day Moving Average of $31.82May 4, 2024 | finance.yahoo.comSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 2, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) Rating Reiterated by Barrington ResearchBarrington Research reissued an "outperform" rating and issued a $71.00 price objective on shares of Surmodics in a research note on Thursday.May 2, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) Releases Earnings Results, Beats Expectations By $0.43 EPSSurmodics (NASDAQ:SRDX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.43. Surmodics had a return on equity of 8.06% and a net margin of 3.99%. The business had revenue of $31.96 million during the quarter, compared to analysts' expectations of $28.79 million. During the same quarter last year, the business posted ($0.40) EPS.May 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)May 2, 2024 | finance.yahoo.comSurmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 1, 2024 | uk.finance.yahoo.comSurmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo FinanceMay 1, 2024 | markets.businessinsider.comSurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating ReaffirmedMay 1, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) PT Lowered to $43.00Needham & Company LLC lowered their target price on shares of Surmodics from $47.00 to $43.00 and set a "buy" rating for the company in a research note on Wednesday.May 1, 2024 | investorplace.comSRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024May 1, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) Issues FY 2024 Earnings GuidanceSurmodics (NASDAQ:SRDX) updated its FY 2024 earnings guidance. The company provided EPS guidance of -0.670--0.470 for the period, compared to the consensus estimate of -0.940. The company also issued revenue guidance of $118.0 millionillion-$120.0 millionillion, compared to the consensus estimate of $119.7 millionillion.May 1, 2024 | businesswire.comSurmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceApril 30, 2024 | markets.businessinsider.comSurModics earnings: here's what Wall Street expectsApril 30, 2024 | finance.yahoo.comCan the 4 Medical Device Stocks Hit Targets This Earnings Season?April 24, 2024 | marketbeat.comSurmodics (SRDX) Set to Announce Quarterly Earnings on WednesdaySurmodics (NASDAQ:SRDX) will be releasing earnings before the market opens on Wednesday, May 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=381142)April 19, 2024 | businesswire.comSurmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1April 17, 2024 | finance.yahoo.comWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowApril 16, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.comStockNews.com upgraded shares of Surmodics from a "buy" rating to a "strong-buy" rating in a report on Tuesday.April 13, 2024 | finance.yahoo.comInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsApril 11, 2024 | marketbeat.comQ1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Investment analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for shares of Surmodics in a research report issued to clients and investors on Tuesday, April 9th. Zacks Research analyst D. Dey now expects that the comApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)April 10, 2024 | marketbeat.comSurmodics' (SRDX) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $47.00 price objective on shares of Surmodics in a report on Wednesday.April 10, 2024 | marketbeat.comQ4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Stock analysts at Zacks Research lifted their Q4 2025 EPS estimates for Surmodics in a note issued to investors on Tuesday, April 9th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.66 per share for the quarter, up from theiMarch 23, 2024 | finance.yahoo.comShould You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?March 22, 2024 | marketbeat.comQ2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystSurmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities researchers at Zacks Research reduced their Q2 2024 earnings per share (EPS) estimates for shares of Surmodics in a note issued to investors on Wednesday, March 20th. Zacks Research analyst D. Dey now forecasts that the company will post earnMarch 21, 2024 | marketbeat.comBrokers Offer Predictions for Surmodics, Inc.'s Q4 2025 Earnings (NASDAQ:SRDX)Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Zacks Research boosted their Q4 2025 earnings per share (EPS) estimates for shares of Surmodics in a research note issued to investors on Wednesday, March 20th. Zacks Research analyst D. Dey now anticipates that the compaMarch 7, 2024 | marketbeat.comKennedy Capital Management LLC Decreases Position in Surmodics, Inc. (NASDAQ:SRDX)Kennedy Capital Management LLC cut its stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 21.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 229,782 shares of the company's stock after selling 63,577 sMarch 2, 2024 | finance.yahoo.comAre Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?February 27, 2024 | businesswire.comSurmodics to Participate in Upcoming Investor Conferences in March and AprilFebruary 22, 2024 | marketbeat.comSurmodics, Inc. (NASDAQ:SRDX) Stock Holdings Lifted by Acadian Asset Management LLCAcadian Asset Management LLC boosted its stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 18.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 354,738 shares of the company's stock after pFebruary 15, 2024 | marketbeat.comSurmodics, Inc. (NASDAQ:SRDX) Short Interest Down 6.9% in JanuarySurmodics, Inc. (NASDAQ:SRDX - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 402,100 shares, a drop of 6.9% from the January 15th total of 432,000 shares. Approximately 3.0% of the company's shares are short sold. Based on an average daily trading volume, of 66,900 shares, the short-interest ratio is presently 6.0 days.February 14, 2024 | marketbeat.comSurmodics, Inc. to Post Q2 2024 Earnings of ($0.34) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Zacks Research reduced their Q2 2024 earnings per share (EPS) estimates for Surmodics in a report released on Monday, February 12th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of ($0.34) per share for the quarterFebruary 8, 2024 | marketbeat.comQ2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Barrington ResearchSurmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Barrington Research reduced their Q2 2024 earnings per share estimates for Surmodics in a report released on Tuesday, February 6th. Barrington Research analyst M. Petusky now expects that the company will post earnings of ($0.36)February 7, 2024 | marketbeat.comBarrington Research Equities Analysts Lower Earnings Estimates for Surmodics, Inc. (NASDAQ:SRDX)Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Stock analysts at Barrington Research reduced their Q2 2025 earnings per share (EPS) estimates for shares of Surmodics in a research report issued on Tuesday, February 6th. Barrington Research analyst M. Petusky now forecasts that the company will posFebruary 6, 2024 | ca.finance.yahoo.comSYK Jun 2024 290.000 putFebruary 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsFebruary 2, 2024 | finance.yahoo.comHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay PacketFebruary 2, 2024 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptFebruary 2, 2024 | finance.yahoo.comSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewFebruary 1, 2024 | marketwatch.comSurmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeilFebruary 1, 2024 | finance.yahoo.comSurmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024February 1, 2024 | msn.comSurmodics beats top-line and bottom-line estimates; updates FY24 outlookFebruary 1, 2024 | finance.yahoo.comSurModics (SRDX) Reports Break-Even Earnings for Q1February 1, 2024 | finance.yahoo.comSurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesFebruary 1, 2024 | marketbeat.comSurmodics (NASDAQ:SRDX) Updates FY 2024 Earnings GuidanceSurmodics (NASDAQ:SRDX) updated its FY 2024 earnings guidance. The company provided EPS guidance of -1.170--0.870 for the period, compared to the consensus estimate of -1.160. The company also issued revenue guidance of $113.0 millionillion-$117.0 millionillion, compared to the consensus estimate of $119.3 millionillion.February 1, 2024 | finance.yahoo.comSurmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceFebruary 1, 2024 | marketbeat.comLos Angeles Capital Management LLC Boosts Stake in Surmodics, Inc. (NASDAQ:SRDX)Los Angeles Capital Management LLC lifted its holdings in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 149.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,916 shares ofJanuary 31, 2024 | benzinga.comA Preview Of Surmodics's EarningsJanuary 22, 2024 | finance.yahoo.comSurmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the KneeJanuary 16, 2024 | finance.yahoo.comSurmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1 Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. SRDX Media Mentions By Week SRDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRDX News Sentiment▼0.000.42▲Average Medical News Sentiment SRDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRDX Articles This Week▼12▲SRDX Articles Average Week Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Orthofix Medical News Today AngioDynamics News Today Accuray News Today Cytosorbents News Today AtriCure News Today Alphatec News Today Bioventus News Today Pulse Biosciences News Today Iradimed News Today OraSure Technologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRDX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford ClubDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
